Aurum Ventures Invests $1.2M in Hebrew U's Yissum for Circulating DNA Test Development | GenomeWeb

NEW YORK (GenomeWeb) – The Hebrew University of Jerusalem's Yissum Research Development Company said today that it has received a $1.2 million investment from Aurum Ventures MKI to support its development of circulating cell-free DNA-based diagnostics for a variety of diseases.

The method Yissum plans to advance is based on the detection of methylation markers in circulating DNA, which can serve as biomarkers for specific disease states in the body.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
06
Sponsored by
Natera

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.